Correspondence to the editorial on “Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease (CHM-2025-1013)”
Yuli Lin1,2, Dongqin Yang1, Zhihao Wu2, Ming Guan1, Chunhua Song3
1Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, Shanghai 200040, China 2Department of Immunology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China 3Division of Hematology, The Ohio State University Wexner Medical Center, the James Cancer Hospital, Columbus, OH 43210, USA
